Identification and analysis of cuproptosis associated molecular clusters and immunological profiles in atopic dermatitis

鉴定和分析特应性皮炎中与铜沉积相关的分子簇和免疫学特征

阅读:1

Abstract

BACKGROUND: Atopic dermatitis (AD) is a chronic skin condition marked by persistent itching and dryness. The role of cuproptosis, a novel form of programmed cell death, in AD is not yet understood. METHODS: The GSE107361 dataset was obtained from the Gene Expression Omnibus (GEO) database. Cuproptosis-related genes (CRGs) in AD were identified and analyzed, and immune landscape analysis was performed using ssGSEA. AD was clustered based on CRGs using ConsensusClusterPlus. Weighted gene co-expression network analysis (WGCNA) and differential gene expression analysis were conducted. Hub genes between AD clusters were identified, and both protein-protein interaction (PPI) and drug-gene interaction networks were developed. RESULTS: Three CRGs (DLD, MTF1, and GLS) were significantly upregulated in the AD group compared to healthy controls. Notably, four core CRGs (LIAS, LIPT1, PDHA1, CDKN2A) distinguished early-onset from adult-onset AD, indicating more active cuproptosis in early-onset AD. CRGs were linked to immune cell infiltration in AD, highlighting differences in immune microenvironments between early- and adult-onset AD. Early-onset AD showed high innate immunity, while adult-onset AD had a mix of innate and type 1 adaptive immunity. CRG expression identified two molecular subtypes with distinct immune infiltration: Cluster 2 (high cuproptosis) had predominant innate immunity, while Cluster 1 (low cuproptosis) had adaptive immunity. Additionally, 102 hub DEGs were identified through WGCNA co-expression network analysis, and 10 hub node genes were identified and potential drugs were explored for the management of AD. CONCLUSIONS: The study provides insights into the roles of cuproptosis-related processes in the pathogenesis and potential treatment of AD. Finding of key hub genes between the 2 distinct immune infiltration subtypes might inform potential therapeutic strategies for AD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。